These results shed light on the mechanisms of GRK6‐P2Y6 signaling in ACC in the development of visceral hypersensitivity and provide a new therapeutic avenue into the treatment of chronic visceral hypersensitivity in patients with IBS. This evidence concerns the gene GRK6 and irritable bowel syndrome.